LAVA Medtech Acquisition Corp. Class A Common Stock
LVAC
LVAC was delisted on the 10th of May, 2023.
0 hedge funds and large institutions have $0 invested in LAVA Medtech Acquisition Corp. Class A Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 54 closing their positions.
100% less funds holding
Funds holding: 54 → 0 (-54)
100% less capital invested
Capital invested by funds: $116M → $0 (-$116M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 54
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Saba Capital Management
New York
|
-$11.2M |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$10.1M |
| 3 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$9.28M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$7.8M |
| 5 |
CCA
Castle Creek Arbitrage
Avon,
Colorado
|
-$6.25M |
LVAC Hedge Fund Activity: Q2 2023 in Review
0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) for Q2 2023, worth a combined $0 — down 100% from $116M a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of LVAC and 0 opened new positions — a net loss of 54 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Saba Capital Management, exiting entirely with an estimated $11.2M sold.
- 0 institutional investors held LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) as of Q2 2023, down from 54 in Q1 2023.
- Funds reported $0 of LAVA Medtech Acquisition Corp. Class A Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new LAVA Medtech Acquisition Corp. Class A Common Stock positions in Q2 2023 and 54 closed out, a net change of -54 holders.
- The largest LAVA Medtech Acquisition Corp. Class A Common Stock seller in Q2 2023 was Saba Capital Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q2 2023.